COMPLETE SKIN CLEARANCE IS NOT ATTAINED BY MOST PATIENTS RECEIVING BIOLOGICS FOR MODERATE TO SEVERE PLAQUE PSORIASIS: INTERIM RESULTS OF AN INTERNATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY

被引：0
|
作者：
Augustin, M. [1 ]
Lacour, J. [2 ]
Reich, K. [3 ]
Horne, L. [4 ]
Williams, A. [4 ]
Horton, J. [5 ]
Slynn, G. [6 ]
Hammond, E. R. [4 ]
机构：
[1] Univ Med Ctr Hamburg, Hamburg, Germany
[2] Hop Archet, Nice, France
[3] Dermatologikum Hamburg, Hamburg, Germany
[4] AstraZeneca, Gaithersburg, MD USA
[5] Clin Solut Grp, Raleigh, NC USA
[6] AstraZeneca, Alderley Pk, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1321
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY7
引用
下载
收藏
页码：A575 / A575
页数：1
相关论文
共 50 条
  • [41] Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with moderate-to-severe plaque psoriasis: Results from the EXCEED study
    Gottlieb, Alice B.
    Merola, Joseph F.
    Reich, Kristian
    Behrens, Frank
    Nash, Peter
    Bao, Weibin
    Pellet, Pascale
    Pricop, Luminita
    McInnes, Iain B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB92 - AB92
  • [42] Efficacy of switching from ustekinumab to guselkumab in patients with moderate-to-severe plaque psoriasis: Results from the NAVIGATE study
    Langley, Richard G.
    Tsai, Tsen-Fang
    Flavin, Susan
    Song, Michael
    Randazzo, Bruce
    Wasfi, Yasmine
    Li, Shu
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB120 - AB120
  • [43] Interim Analysis of the non-interventional Study TILOT: Efficacy of Tildrakizumab for the Treatment of Patients with moderate to severe Plaque Psoriasis under Practical Conditions
    Tsianakas, A.
    Kirsch, A.
    Diemert, S.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 39 - 39
  • [44] Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)
    Armstrong, April W.
    Riedl, Elisabeth
    Brunner, Patrick M.
    Piaserico, Stefano
    Visser, Willie I.
    Haustrup, Natalie
    Konicek, Bruce W.
    Kadziola, Zbigniew
    Nunez, Mercedes
    Brnabic, Alan
    Schuster, Christopher
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [45] Real-world effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis: Week 28 interim analysis of a Phase 4 study
    Bhatia, Neal
    Heim, Jayme
    Torres, Monique
    Beute, Paulita
    Rozzo, Stephen J.
    Vasquez, J. Gabriel
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 6 - 7
  • [46] Real-world effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis: Week 28 interim analysis of a phase 4 study
    Bhatia, Neal
    Heim, Jayme
    Torres, Monique
    Beute, Paulita
    Rozzo, Stephen J.
    Vasquez, J. Gabriel
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB199 - AB199
  • [47] A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study
    Zagni, Emanuela
    Bianchi, Luca
    Fabbrocini, Gabriella
    Corrao, Salvatore
    Offidani, Annamaria
    Stingeni, Luca
    Costanzo, Antonio
    Pellacani, Giovanni
    Peris, Ketty
    Bardazzi, Federico
    Argenziano, Giuseppe
    Ruffolo, Silvana
    Dapavo, Paolo
    Carrera, Carlo
    Fargnoli, Maria Concetta
    Parodi, Aurora
    Romanelli, Marco
    Malagoli, Piergiorgio
    Talamonti, Marina
    Megna, Matteo
    Raspanti, Massimo
    Paolinelli, Matteo
    Hansel, Katharina
    Narcisi, Alessandra
    Conti, Andrea
    De Simone, Clara
    Chessa, Marco Adriano
    De Rosa, Alina
    Provenzano, Eugenio
    Ortoncelli, Michela
    Moltrasio, Chiara
    Fidanza, Rosaria
    Burlando, Martina
    Tonini, Annalisa
    Gaiani, Francesca Maria
    Simoni, Lucia
    Zullo, Alessandro
    Fiocchi, Martina
    Colombo, Delia
    BMC HEALTH SERVICES RESEARCH, 2021, 21 (01)
  • [48] A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study
    Emanuela Zagni
    Luca Bianchi
    Gabriella Fabbrocini
    Salvatore Corrao
    Annamaria Offidani
    Luca Stingeni
    Antonio Costanzo
    Giovanni Pellacani
    Ketty Peris
    Federico Bardazzi
    Giuseppe Argenziano
    Silvana Ruffolo
    Paolo Dapavo
    Carlo Carrera
    Maria Concetta Fargnoli
    Aurora Parodi
    Marco Romanelli
    Piergiorgio Malagoli
    Marina Talamonti
    Matteo Megna
    Massimo Raspanti
    Matteo Paolinelli
    Katharina Hansel
    Alessandra Narcisi
    Andrea Conti
    Clara De Simone
    Marco Adriano Chessa
    Alina De Rosa
    Eugenio Provenzano
    Michela Ortoncelli
    Chiara Moltrasio
    Rosaria Fidanza
    Martina Burlando
    Annalisa Tonini
    Francesca Maria Gaiani
    Lucia Simoni
    Alessandro Zullo
    Martina Fiocchi
    Delia Colombo
    BMC Health Services Research, 21
  • [49] Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis
    Viswanathan, Hema N.
    Chau, Dina
    Milmont, Cassandra E.
    Yang, Wenjjing
    Erondu, Ngozi
    Revicki, Dennis A.
    Klekotka, Paul
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (03) : 235 - 239
  • [50] Bimekizumab efficacy in patients with moderate to severe plaque psoriasis receiving continuous bimekizumab or switching from adalimumab: Results from the phase 3 BE SURE trial
    Strober, Bruce E.
    Pinter, Andreas
    Warren, Richard B.
    Blauvelt, Andrew
    Sebastian, Michael
    De Cuyper, Dirk
    Vanvoorden, Veerle
    Wang, Maggie
    Madden, Cynthia
    Gooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB138 - AB138
12345